John Sourbeer
Stock Analyst at UBS
(0.99)
# 3,870
Out of 5,044 analysts
40
Total ratings
45%
Success rate
-14.57%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Maintains: Buy | $320 → $355 | $287.22 | +23.60% | 5 | Oct 24, 2025 | |
| QGEN Qiagen | Maintains: Neutral | $48 → $50 | $48.40 | +3.31% | 5 | Aug 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $170 → $240 | $182.03 | +31.85% | 2 | Jul 25, 2025 | |
| CYRX Cryoport | Maintains: Buy | $10 → $11 | $10.40 | +5.77% | 6 | Apr 1, 2025 | |
| STVN Stevanato Group | Maintains: Neutral | $24 → $24 | $25.98 | -9.55% | 2 | Mar 7, 2025 | |
| QDEL QuidelOrtho | Maintains: Neutral | $43 → $45 | $29.48 | +52.65% | 4 | Feb 13, 2025 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $2.09 | -4.31% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $100.35 | +44.49% | 3 | Nov 5, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $596.48 | -19.53% | 4 | Mar 8, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $38.64 | +163.98% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $13.59 | +267.92% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $127.18 | +0.64% | 2 | Jul 27, 2022 |
West Pharmaceutical Services
Oct 24, 2025
Maintains: Buy
Price Target: $320 → $355
Current: $287.22
Upside: +23.60%
Qiagen
Aug 7, 2025
Maintains: Neutral
Price Target: $48 → $50
Current: $48.40
Upside: +3.31%
ICON Public Limited Company
Jul 25, 2025
Maintains: Buy
Price Target: $170 → $240
Current: $182.03
Upside: +31.85%
Cryoport
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $11
Current: $10.40
Upside: +5.77%
Stevanato Group
Mar 7, 2025
Maintains: Neutral
Price Target: $24 → $24
Current: $25.98
Upside: -9.55%
QuidelOrtho
Feb 13, 2025
Maintains: Neutral
Price Target: $43 → $45
Current: $29.48
Upside: +52.65%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $2.09
Upside: -4.31%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $100.35
Upside: +44.49%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $596.48
Upside: -19.53%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $38.64
Upside: +163.98%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $13.59
Upside: +267.92%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $127.18
Upside: +0.64%